Newron’s commercialization partner Zambon and Valeo Pharma announce the launch of Onstryv® (safinamide) for Parkinson’s disease in Canada

37

MILAN & MONTREAL–(BUSINESS WIRE)–Newron and its partner Zambon S.p.A. and Valeo Pharma Inc. announced today the launch of Onstryv® for the treatment of Parkinson’s disease in Canada.

 

 

http://www.businesswire.com/news/home/20190710005588/en/Newron%E2%80%99s-commercialization-partner-Zambon-Valeo-Pharma-announce/